Immunservice GmbH develops biomimetic immune hormones, in particular interleukin-2, for safer, more effective and potentially curative therapies, especially in cancer.
Dr. Michael Otto Invests in Innovate Immunotherapy to Prevent and Eliminate Cancer and Viral Infections
Immunservice GmbH has concluded a new round of financing (Series C) to secure development of the company's biological immunotherapy methods for the long term. Joining the existing consortium of investors comprised of Helmut Ponath, the Hubertus-Wald-Stiftung, the High-Tech-Gründerfonds (HTGF) and Hartwig Huland in the latest successful financing round was Dr. Michael Otto, entrepreneur and Chairman of the Board at the Otto Group. "The Immunservice team is thrilled with the personal suppor
20. Jul 2007